Andy Goren
Prof. Dr. Andy Goren has over 20 years of experience in the development and commercialization of breakthrough technologies in the medical, biotechnology and semiconductor fields. Among the list of many firsts in dermatology, Prof Goren was the first to develop a commercial genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to commercialize an acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to commercialize a rapid test for predicting minoxidil response in androgenetic alopecia. Prof. Goren recently completed the development, commercialization, and listing with the U.S. FDA of a breakthrough topical drug for vitiligo, psoriasis and atopic dermatitis. The drug, Photocil, selectively filters NB-UVB from natural sunlight thus increasing patient compliance and convenience over artificial phototherapy. His latest research involves the development of dermatology therapies based on genetically modified organisms. Prof. Goren currently serves as a contract Professor of Dermatology at Universita' degliStudi di Roma "G.Marconi". He is an honorary as well as ordinary member of several dermatology societies world-wide, a scientific reviewer for Dermatologic Therapy, a lecturer in several international dermatology societies, and held numerous appearances and interviews on mainstream TV, radio, and prestigious newspapers. His accomplishments include several patents and publications related to his inventions and discoveries. Prior to his work in Dermatology, Professor Goren developed a medical device to correct gait disorders in peripheral neuropathy patients using sensory substitution, as well as invent the first wire-free electric charger for mobile devices.
Submit Manuscript
CCRR welcomes direct submissions of manuscripts from authors. You can submit your manuscript to:submissions@oatext.comalternatively to:editor.ccrr@oatext.com
Publication Charges
Clinical Case Reports and Reviewsis an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License". In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.
The publication charges for Clinical Case Reports and Reviews are USD 2890.
Frequently Asked Questions (FAQs)
Why are your charges set at these levels?
All articles published in OA Text are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in OA Text Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.
Our financial goals are to:
- Recover capitalization costs;
- Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development;
- Bend the publication-charge cost downward over time.
Who will pay the APC?
通讯作者或Co-authors has to make the payment on acceptance of the article.
When should I pay?
Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.
*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.
How do I pay?
Authors or institutions can make payments by two modes as per their convenience.
- Wire/Bank transfer
- Card payment
Note:No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction charges may be levied on the author.
Can I be eligible for wavier on APC?
The waiver request will be considered on a case-by-case basis, and will be provided accordingly.
*The Waiver requests must be made during the submission process and will not be accepted after processing of the manuscript.
Do I have to pay if my manuscript is rejected?
不,汽车列车le processing charges will not be applicable for articles rejected by the Editorial office.
Withdrawal Charges
Are reprints of my article included in the article processing charges (APCs)?
不,汽车列车le processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.
Special Issues
Controversies in Multiple Sclerosis
Editor Affiliation:
Dr. Jagannadha Avasarala, MD, PhD
University of South Carolina School of Medicine, USA
Submission date: May 30, 2016
Publication date: July 30, 2016
Description of the Special Issue: Controversies in multiple sclerosis (MS), like any other disease, are nothing new. Even after decades of understanding the disease process, fundamental differences exist in such mundane issues as how to define a relapse. Is it enough that a new symptom developed and has persisted for a few days, for example? Is there a consensus to define relapses as clinicalandradiological events? If MRI is so sensitive, why not insist on every patient with a ‘relapse’ be screened radiologically and not rely on clinical evidence or lack thereof? Is it a cost issue? This is one such niggling issue that needs clarity.
Some of the topics included in this special edition are how to define secondary progressive MS (SPMS) and how radiological features might or might not contribute to the diagnostic approach, if radiologically isolated syndrome (RIS) is different in patients with symptoms vs asymptomatic individuals, why clinically isolated syndrome patients are not routinely subjected to analysis of their cerebrospinal fluid if their MRI data are not supportive, why African Americans need to be screened for Vitamin D deficiency in MS patients and treated if levels are found to be low, particularly if there is minimal evidence that it confers any benefit, and lastly if there are trends or patterns in patients with progressive multifocal leukoencephalopathy (PML) who are enrolled in the TOUCH program with respect to their JCV Ab status.
Imaging of myocardial diseases: to new horizons
Editor Affiliation:
Valentin E. Sinitsyn
Professor
Department of Radiology
Federal Center of Medicine and Rehabilitation
Russia
Submission date: July 15, 2016
Publication date: August 15, 2016
描述的特殊问题:诊断影像ng in non-coronary myocardial diseases is a very intriguing topic both for research and clinical practice. Different forms of cardiomyopathies, acute and chronic myocarditis, secondary involvement of the heart in different systemic diseases are very difficult to diagnose. Cardiac imaging - first of all, CT, MRI and hybrid modalities - offers unique opportunities for detection and characterization of this pathology. Late-enhancement MRI, T1-mapping, low-dose CT-angiography and dual-energy CT provide new insights into myocardial structure and function. Nevertheless, questions about proper choice of imaging modality remain. Is T1-mapping or late-enhancement CT enough sensitive to detect focal or diffuse myocardial inflammation of fibrosis? How cardiac imaging can help to differentiate between primary and secondary cardiomyopathies? Articles published in this issue will give some insight into these and some other challenges in cardiovascular radiology and imaging. This issue also will present some rare cases of various myocardial diseases.
Mental Health and Psychological Well-being
Editor Affiliation:
Dr. Jungeun Lee, PhD
LPC Angelo State University
USA
Submission date: January 25, 2017
Publication date: March 25, 2017
Description of the Special Issue: Mental disorders can cause a various kinds of challenges and struggles in lives of many people, which may jeopardize not only their sense of well-being but also their relationships with family, friends, and colleagues. Mental health is defined not just the absence of mental illness or psychological distress, but a state of well-being embracing a person’s own potential toward productivity in and contribution to the community. This special issue invites all concerned researchers and practitioners from the different fields to address clinical cases of various topics related to mental health and psychological well-being. This special issue will contribute to the literature on mental health by including collecting important clinical cases of various mental disorders and their impact on emotional, social, and physical well-being as well as evidences for the efficacy of different treatments and the relative efficacy of medication and traditional talk therapy, or their combination. We hope to draw a meaningful attention to mental health and psychological well-being and to provide a context for practitioners to conceptualize clinical cases through this special issue of Clinical Case Reports and Reviews.
Challenges in Developing Neurorehabilitation Services in Developing World
Editor Affiliation:
Dr. Nirmal Surya, M.D., D.N.B (Neuro)
Chairman, Surya Neuro Center
India
Submission date: January 31, 2019
Publication date: May 15, 2019
Description of the Special Issue: Neurorehabilitation is the part of Neurology which hasn’t been addressed properly in the developing world, due to either lack of expertise, lack of knowledge or lack of funds and infrastructure. This Special issue is a broad-based journal found on the following points- To publish the challenges faced by medical professionals in developing medical rehabilitation services in different parts of the world, to understand the challenges faced by different members in a multi-disciplinary Neurorehabilitation team.
Prof. Dr. Andy Goren has over 20 years of experience in the development and commercialization of breakthrough technologies in the medical, biotechnology and semiconductor fields. Among the list of many firsts in dermatology, Prof Goren was the first to develop a commercial genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to commercialize an acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to commercialize a rapid test for predicting minoxidil response in androgenetic alopecia. Prof. Goren recently completed the development, commercialization, and listing with the U.S. FDA of a breakthrough topical drug for vitiligo, psoriasis and atopic dermatitis. The drug, Photocil, selectively filters NB-UVB from natural sunlight thus increasing patient compliance and convenience over artificial phototherapy. His latest research involves the development of dermatology therapies based on genetically modified organisms. Prof. Goren currently serves as a contract Professor of Dermatology at Universita' degliStudi di Roma "G.Marconi". He is an honorary as well as ordinary member of several dermatology societies world-wide, a scientific reviewer for Dermatologic Therapy, a lecturer in several international dermatology societies, and held numerous appearances and interviews on mainstream TV, radio, and prestigious newspapers. His accomplishments include several patents and publications related to his inventions and discoveries. Prior to his work in Dermatology, Professor Goren developed a medical device to correct gait disorders in peripheral neuropathy patients using sensory substitution, as well as invent the first wire-free electric charger for mobile devices.